Medicines Co's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Medicines Co (MDCO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Medicines Co vs Its Competitors
- TTM: Trailing 12-month revenue of 85M vs 320,668M combined for its competitors (0.0% combined share).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Medicines Co vs. its Competitors, Q3 2019
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Medicines Co reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Medicines Co and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Medicines Co | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Medicines Co's competitor groups requires a Commercial License.
Medicines Co's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Medicines Co | - | - | - | No |
| Competitors combined (51) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDCO Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Immunovant Inc | 282.9% | Outperformed |
| 5 | Xencor Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Medicines Co's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Medicines Co
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Medicines Co |
6,802.95 | 85.03 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Gilead Sciences Inc |
208,779.39 | 30,988.00 |
 Abbott Laboratories |
191,605.90 | 46,585.00 |
 Pfizer Inc |
169,021.89 | 63,625.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
| SUBTOTAL | 1,528,021.78 | 329,936.13 |
Sign in to see all competitors of Medicines Co.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Medicines Co versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Medicines Co's Competitors Named by the Company
Competitive relationships identified from Medicines Co reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Keros Therapeutics Inc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Biocardia Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Zoetis Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Immunovant Inc | Company report | 85% |
| Mira Pharmaceuticals Inc | Company report | 85% |
| Organon and Co | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Pharmacyte Biotech Inc | Company report | 85% |
| Bullfrog Ai Holdings Inc | Company report | 85% |
| Telomir Pharmaceuticals Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Lantern Pharma Inc | Company report | 85% |
| Neurocrine Biosciences Inc | Company report | 85% |
| Alterola Biotech Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Barinthus Biotherapeutics Plc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Zevra Therapeutics Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Inmune Bio Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| 180 Life Sciences Corp | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Zentalis Pharmaceuticals Inc | Company report | 85% |
| Catalent Inc | Company report | 85% |
| Gt Biopharma Inc | Company report | 85% |
| Lyell Immunopharma Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Anebulo Pharmaceuticals Inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Vaxart Inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Medicines Co's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Medicines Co's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Zoetis Inc | United States 52.11 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Medicines Co's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Medicines Co | 6,803 | - | - |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Gilead Sciences Inc | 208,779 | 1,822,824 | -227,235 |
| Abbott Laboratories | 191,606 | 405,087 | 47,174 |
| Pfizer Inc | 169,022 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| PEERS TOTAL | 1,521,219 | 801,567 | 50,209 |
Medicines Co's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Abbott Laboratories | Non-US 57.70 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Medicines Co's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | -107.4x | 4.3x | -111.6x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -25.55 % | -9.83 % (avg) | -15.72 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Medicines Co's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|
| Revenue Growth | 23.14 % | 5.31 % | -57.34 % | -53.67 % | -68.71 % | - |
| Operating Margin | 1.92 % | -8.91 % | -88.18 % | - | - | - |
| Return on Invested Capital | 0.75 % | -2.57 % | -10.65 % | -16.61 % | -56.34 % | -26.03 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Medicines Co's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (38.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-38.2% annualized).
Methodology: see Methodology: SWOT Analysis.
Medicines Co's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Medicines Co | 1.68 | 2.07 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Medicines Co's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Medicines Co | Q3 2019 | - | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| PEERS TOTAL | +6.4 % | -37.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Medicines Co's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Medicines Co | Q3 2019 | - | - |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
Medicines Co's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Medicines Co | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Gilead Sciences Inc | - | - | - |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Medicines Co's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Medicines Co | - | 80.01 |
| Merck and Co Inc | 118.32 | 5.44 |
| Gilead Sciences Inc | - | 6.74 |
| Abbott Laboratories | 35.35 | 4.11 |
| Pfizer Inc | 41.83 | 2.66 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| PEERS AVERAGE | 74.81 | 4.63 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.